News | Lung Imaging | May 31, 2024

Medical imaging AI innovator debuts vision of  early lung cancer detection and care  

Qure.ai unveils its AI-powered lung cancer care continuum unveiled at ASCO 2024

May 31, 2024 — To further the fight against global lung cancer, Qure.ai, a leader in healthcare artificial intelligence (AI), will unveil its AI-powered lung cancer continuum at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, from May 31 to June 4, 2024.

Featuring AI solutions to identify, measure, manage, and monitor, the end-to-end care continuum is designed to support clinicians and advance developments for lung health in the pharmaceutical and medical device industries. 

“Lung cancer is the leading cause of cancer-deaths worldwide, with approximately 75% of patients detected in late-stage disease. Earlier detection reduces the need for therapeutic or surgical intervention and boosts survival rates, by over 90% if treatment starts at stage 1,” states Prashant Warier, CEO and Co-founder of Qure.ai.  

“Artificial intelligence for lung cancer powers early detection - not just as part of existing screening programs, but by finding small pulmonary nodules, often opportunistically, during general healthcare imaging procedures. This enables earlier identification and referral for imaging or treatment pathways. It also helps overcome the ongoing challenges of low lung cancer screening appointment uptake rates,” Prashant Warier adds. 

The Qure.ai lung cancer continuum provides regulatory-cleared* individual or end-to-end detection, analysis, and monitoring tools, putting improved patient care at the heart of innovation: 

·         AI to identify missed lung nodules from chest X-rays and support in early lung cancer diagnosis; 

·         AI to measure lung nodules via CT scans and track volumetric growth as part of progression monitoring; 

·         AI to manage lung cancer cases via multi-modality reporting, collaboration and prioritization tools; 

·         AI to monitor drug efficacy and disease progression in clinical trials and cancer care research. 

For more information: www.qure.ai 

*Global clearances such as FDA and EU MDR CE vary across geographies. 


Related Content

News | Ultrasound Imaging

June 4, 2025 — RadNet, Inc., a provider of high-quality, cost-effective diagnostic imaging services and digital health ...

Time June 09, 2025
arrow
News | Mammography

June 9, 2025 — A new independent, peer-reviewed study published in the journal Clinical Breast Cancer reinforces the ...

Time June 09, 2025
arrow
News | Imaging Software Development

June 05, 2025 — Nano-X Imaging Ltd. has announced that its deep-learning medical imaging analytics subsidiary, Nanox AI ...

Time June 05, 2025
arrow
News | Prostate Cancer

June 5, 2025 – Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer ...

Time June 05, 2025
arrow
News | Ultrasound Imaging

June 3, 2025 — In a collaborative study between the Departments of Radiology at the Children’s Hospital of Philadelphia ...

Time June 04, 2025
arrow
News | Breast Imaging

June 2, 2025 — Clairity, Inc., a digital health innovator advancing AI-driven healthcare solutions, has received U.S ...

Time June 02, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

Hyperfine, Inc., producer of the world’s first FDA-cleared AI-powered portable MRI system for the brain — the Swoop ...

Time May 29, 2025
arrow
News | Imaging Software Development

May 27, 2025 — DeepLook Medical, a company advancing medical imaging through visual enhancement technology, recently ...

Time May 28, 2025
arrow
News | Imaging Software Development

May 20, 2025 – Intelerad, a provider of medical imaging software solutions, recently announced its prime partnership ...

Time May 21, 2025
arrow
News | Teleradiology

May 21, 2025 — Konica Minolta Healthcare Americas, Inc and NewVue have announced the introduction of Exa Teleradiology ...

Time May 21, 2025
arrow
Subscribe Now